Introduction {#Sec1}
============

Nicotinamide phosphoribosyltransferase (NAMPT), formerly known as visfatin or pre-B cell colony enhancing factor (PBEF), is a protein that has been implicated in various pathophysiological conditions, although some of these ascribed features are controversial and are still being discussed. Originally, NAMPT had been identified as PBEF \[[@CR1]\], a cytokine capable of stimulating the maturation of B cell precursors. NAMPT attracted most attention, however, when it was re-discovered as an adipocytokine named 'visfatin' and claimed to be predominantly secreted from visceral adipose tissue, exerting insulin-like actions \[[@CR2]\]. More recently, NAMPT has been identified as the crucial NAD biosynthetic enzyme \[[@CR3]\] and thereby to play an important role in the regulation of cellular metabolism and insulin secretion \[[@CR4], [@CR5]\].

So far, clinical studies in adults have provided controversial findings concerning the role of NAMPT in obesity and glucose metabolism \[[@CR6]\], with positive, negative or no associations found \[[@CR7]--[@CR10]\]. In addition, knowledge of the main origin of NAMPT is still elusive \[[@CR11], [@CR12]\]. Nevertheless, no matter which potential NAMPT function is considered (NAD biosynthetic enzyme, pro-inflammatory cytokine and/or adipocytokine), NAMPT may have acute as well as chronic associations with obesity and may influence major metabolic functions. In particular, the direct interactions with sirtuin-1 (SIRT1), a key mediator that coordinates metabolic responses to nutritional availability, are of interest \[[@CR13], [@CR14]\].

Paediatric cohorts allow a less biased exploration of the clinical context and potential underlying mechanisms linking NAMPT with obesity and glucose metabolism, as they are less confounded by co-morbidities and their treatment than adult cohorts. Studies in children have indeed revealed that circulating NAMPT was elevated in obesity but failed to detect a direct association with BMI \[[@CR15], [@CR16]\].

In this study, we not only provide clinical evidence of the association of NAMPT with obesity and related metabolic and cardiovascular sequelae, but also show that NAMPT is acutely downregulated after glucose provocation. In particular, we identify leucocytes as a major source of enzymatically active NAMPT and reveal that the association of circulating NAMPT with leucocyte count outranges that with obesity.

Methods {#Sec2}
=======

Cohort and patient characteristics {#Sec3}
----------------------------------

**Leipzig Schoolchildren cohort** This is a representative cohort of the Leipzig paediatric population with detailed characterisation of anthropometric and biochemical variables of physical and pubertal maturation \[[@CR17]\]. We have selected 134 children that have been previously evaluated for the dynamics of adipocytokines during pubertal development (see Electronic supplementary material \[ESM\] Table [1](#MOESM1){ref-type=""}) \[[@CR18]\].

**Leipzig Atherobesity Childhood cohort** We recruited 86 obese white children and adolescents and 70 lean controls of similar age, sex and pubertal stage (ESM Table [2](#MOESM2){ref-type=""}).Fasting blood samples were obtained at 08:00 hours and were immediately centrifuged, aliquoted and stored at −80°C. Metabolic variables were analysed by a certified laboratory. Insulin and C-peptide were measured using the Liaison C-peptide and insulin luminescence immunoassay on the Liaison analyzer (DiaSorin, Saluggia, Italy). Analytical sensitivity of these test systems was 1.2 and 3 pmol/l, respectively. Mean intra- and interassay coefficients of variation were below 4.1% for insulin and 4.4% for C-peptide.An OGTT was performed in all participants. HOMA-IR \[[@CR19]\] and Matsuda insulin sensitivity index (ISI) \[[@CR20]\] were calculated as measures of insulin sensitivity. Ambulatory blood pressure monitoring was performed for 24 h (SpaceLabs Medical Inc., Redmond, USA); a recording was considered successful if \>80% of readings were valid. Endothelial function was evaluated by the reactive hyperaemia index (RHI), and intima media thickness (IMT) by high-resolution B-mode ultrasound as described previously \[[@CR21]\].

**Lifestyle intervention cohort** Thirty-six obese children (ESM Table [3](#MOESM3){ref-type=""}) completed the 1-year lifestyle intervention 'Obeldicks' as described in detail elsewhere \[[@CR22]\].

**Bariatric surgery intervention cohort** Fourteen extremely obese patients (ten adults, four adolescents; ESM Table [3](#MOESM3){ref-type=""}) were subjected to bariatric surgery by sleeve gastrectomy for clinical indications according to current guidelines of the Bariatric Scientific Collaborative Group and the American Pediatric Surgical Association \[[@CR23], [@CR24]\]. We obtained serum samples before and 6 months after surgery in all patients.

**Exercise intervention cohort** Fifteen young healthy, lean adults (ESM Table [3](#MOESM3){ref-type=""}) participated in a 6 month exercise programme consisting of sessions on 3 days of the week. Each training session included 20 min biking or running, 45 min circuit training and 20 min warming-up and cooling-down periods. At baseline and after 6 months of training, blood samples were obtained in the fasting state.In all cohorts, height was measured to the nearest 0.1 cm and weight to the nearest 0.1 kg using a digital balance. In children, BMI data were standardised by age and sex applying German reference data \[[@CR25]\], and given as the BMI standard deviation score (SDS). A cutoff of ≥1.23 and ≥1.88 SDS (90th and 97th centile) classified the children as being overweight or obese. Detailed inclusion criteria for all cohorts are given in supplementary methods (see ESM [Methods](#MOESM7){ref-type=""}).Written informed consent was obtained from all parents and from children ≥12 years. All studies were approved by the local ethics committees of the Universities of Leipzig and Witten/Herdecke (reg. nos.: 782-1998 (schoolchildren), 029-2006 (Atherobesity cohort), 341-1 (adolescent bariatric surgery), 031-2006 (adult bariatric surgery), 274-2008 (exercise study), 64/2001 and 15/2006 ('Obeldicks').

Quantification of endothelial progenitor cells in peripheral blood {#Sec4}
------------------------------------------------------------------

Endothelial progenitor cells (EPCs) were determined as CD34 and kinase insert domain receptor (KDR) double-positive cells applying flow cytometry \[[@CR26]\] (Beckman Coulter Epics XL, Krefeld, Germany). Number of EPCs is given as EPCs per 500,000 counted cells.

Isolation, cultivation and stimulation of leucocytes and subpopulations {#Sec5}
-----------------------------------------------------------------------

Cells were isolated applying density gradient centrifugation (Biocoll Separating Solution, Biochrom, Germany) of 20 ml peripheral blood from 12 children and adolescents (age, 11.7 ± 2.7 years; BMI SDS, 2.14 ± 1.12). An incubation step of 2 h at 37°C in RPMI medium containing 0.5% FCS, penicillin and streptomycin (culture medium \[CM\]) was used for separation of monocytes and lymphocytes. Cell fractions were cultivated in CM for 6 h at 37°C before harvesting of cells and supernatant fractions. Cell integrity was confirmed by Trypan Blue staining and lactase dehydrogenase assay (BIOCAT, Heidelberg, Germany).

For stimulation experiments, granulocytes and monocytes were incubated in CM supplemented with 1 μg/ml lipopolysaccharide (LPS; Sigma), 40 mmol/l [d]{.smallcaps}-glucose and 40 mmol/l [l-]{.smallcaps}glucose as osmotic control for 24 h at 37°C before harvesting of cells and supernatant fractions.

In addition, leucocytes were isolated from peripheral blood after oral glucose provocation at 0, 60 and 120 min, and cultivated in CM for 45 min before harvest of cells and supernatant fractions.

Analysis of *NAMPT* and *SIRT1* mRNA expression {#Sec6}
-----------------------------------------------

We obtained commercially available tissue RNAs (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) and cDNAs (Biochain, Heidelberg, Germany). RNA from cell fractions was extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany). Reverse transcription was performed using 200 U M-MLV reverse transcriptase per microgram total RNA with oligo (dT) primers. *NAMPT* and *SIRT1* mRNA expression was determined using quantitative real-time PCR with TaqMan probe-based gene expression assay on the ABI 7500 Sequence Detection System (Applied Biosystems, Darmstadt, Germany). To normalise gene expression, housekeeping genes beta actin (*ACTB*), *TBP* and *HPRT* were quantified simultaneously in each sample.

Quantification of NAMPT and enzyme activity in serum samples, cell lysates and supernatant fractions {#Sec7}
----------------------------------------------------------------------------------------------------

NAMPT concentrations were measured by ELISA following the manufacturer's protocol (Adipogen, Seoul, South Korea). Assay quality variables including sensitivity and specificity have been validated previously \[[@CR27]\]. NAMPT amounts in cell lysates and supernatant fractions were normalised to total protein amount (BCA Protein Assay, Thermo Fisher Scientific, Bonn, Germany).

Preparation of samples and determination of enzymatic activity were performed according to the method by Elliott et al. \[[@CR28]\] with minor modifications \[[@CR12], [@CR28]\] (see ESM [Methods](#MOESM7){ref-type=""}).

Statistical analyses {#Sec8}
--------------------

Logarithmic transformation of non-normally distributed data was performed before analysis. For comparison of quantitative traits between two groups, two-tailed Student's *t* test was applied. For more groups and time courses ANOVA was applied, and for categorical data *χ*^2^ test was applied. Correlation analyses were performed using Pearson correlation analysis or partial correlation analysis with adjustment for BMI SDS. For multiple regression analyses, the stepwise forward model was employed. For all tests, the significance level was set at 0.05. Statistical analyses were performed using the software package Statistica 7.1 (StatSoft, Tulsa, OK, USA).

Results {#Sec9}
=======

Association of NAMPT with normal development in healthy lean children {#Sec10}
---------------------------------------------------------------------

We identified no differences in circulating NAMPT levels with progression through puberty in normal healthy lean boys or girls (ESM Fig. [1](#MOESM4){ref-type=""}a). Also, there was no correlation between NAMPT levels and height SDS, circulating IGF-I and markers of pubertal development and adrenarche, including oestradiol, testosterone or dehydroepiandrosterone-sulfate (DHEA-S). There were no differences between boys and girls in the entire cohort (ESM Fig. [1](#MOESM4){ref-type=""}b) or if analysis was restricted to adolescent children.

Association of NAMPT with obesity and obesity interventions {#Sec11}
-----------------------------------------------------------

We applied the Leipzig Atherobesity Childhood cohort (ESM Table [2](#MOESM2){ref-type=""}) to evaluate differences in NAMPT serum concentrations between lean and obese children. NAMPT levels were significantly higher in the obese children compared with lean controls (Fig. [1a](#Fig1){ref-type="fig"}). NAMPT levels correlated with BMI (Fig. [1b](#Fig1){ref-type="fig"}) and other variables of obesity and body fat, including BMI SDS as a normalised index of the degree of overweight, leptin as a biomarker of fat mass, and skinfold thickness as an index of subcutaneous fat (Table [1](#Tab1){ref-type="table"}). Fig. 1NAMPT association with obesity. **a** Obese children (*n* = 86) had significantly higher NAMPT levels (*p* = 0.031) compared with lean children (*n* = 70). Data are mean ± SEM. **b** NAMPT serum levels correlated with BMI (*r* = 0.35, *p* \< 0.001). **c** Changes of NAMPT levels and BMI after 1-year lifestyle intervention in obese children and adolescents (*n* = 36), 6 months following bariatric surgery in severely obese adults and adolescents (*n* = 14), and 6 month exercise programme in normal weight adults (*n* = 15). Data for BMI (open bars) and NAMPT levels (black bars) are given relative to the basal situation (hatched bar), which was set to 1.0. Data are mean ± SEM. Statistical significance was assessed by paired *t* test. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001Table 1Association of NAMPT levels with anthropometric, metabolic and cardiovascular variables in lean and obese children of the Leipzig Atherobesity Childhood cohort (*n* = 156)VariableUnivariate correlationPartial correlation*rp* value*r*^a^*p*^a^ valueAnthropometric variablesBMI SDS0.31\<0.0001BMI (kg/m^2^)0.35\<0.0001Serum leptin (ng/ml)^b^0.250.007WHR0.060.426Skinfold thickness (cm)0.31\<0.0001Metabolic variablesFasting BG (mmol/l)0.260.0010.070.401120 min BG (mmol/l)0.200.0120.130.129Mean BG (mmol/l)0.250.0010.210.009AUC BG (mmol/l × min)0.28\<0.00010.230.004FPI^b^ (pmol/l)0.260.0010.080.346Peak insulin^b^ (pmol/l)0.240.0030.100.237AUC~Ins~^b^ (pmol/l × min)0.270.0010.130.124HOMA-IR^b^0.230.0040.110.395Matsuda ISI^b^−0.29\<0.0001−0.090.112Belfiore ISI−0.31\<0.0001−0.190.021AUC~Ins~/AUC~BG~ (pmol/mmol)0.240.0030.100.215Cardiovascular variablesSystolic BP (mmHg)0.200.0120.090.241Diastolic BP (mmHg)0.090.2260.030.676Mean systolic BP in 24 h (mmHg)0.180.0430.060.491Mean diastolic BP in 24 h (mmHg)0.100.2470.060.515IMT (cm)0.110.174−0.040.582Endothelial function (RHI)−0.230.004−0.100.232EPC count (per 50,0000 counts)^b^−0.29\<0.0001−0.250.002EPC migration^b^0.010.8710.040.669WBC count (×10^9^/l)^b^0.49\<0.00010.44\<0.0001hsCrP (ng/ml)^b^0.34\<0.00010.270.001Pearson correlation analysis was performed for log-transformed NAMPT serum levels, *n* = 156BP, blood pressure; FPI, fasting plasma insulin; Ins, insulin^a^Pearson partial correlation analysis adjusted for BMI SDS^b^Indicates log-transformed variables

We further assessed NAMPT serum concentrations in the context of three distinct intervention studies: (1) a 12 month lifestyle intervention programme in children and adolescents; (2) bariatric surgery by sleeve gastrectomy in severely obese adolescents and adults; and (3) a 6 month exercise intervention in normal weight young healthy adults (ESM Table [3](#MOESM3){ref-type=""}). The strategies differed in the extent of weight loss and improvement of HOMA-IR achieved (Fig. [1c](#Fig1){ref-type="fig"}, ESM Table [3](#MOESM3){ref-type=""}).

After both the bariatric surgery and the exercise interventions we found significantly lower NAMPT serum concentrations, whereas we observed no significant change after lifestyle intervention (Fig. [1c](#Fig1){ref-type="fig"}). The decrease in NAMPT correlated significantly with the decrease in BMI in the surgery group only (ESM Fig. [2](#MOESM5){ref-type=""}d).

In addition to BMI, the bariatric surgery group showed the strongest decrease in white blood cell count (WBC) and high-sensitivity C-reactive protein (hsCrP; ESM Fig. [2](#MOESM5){ref-type=""}a--c) and there was a significant correlation between decrease in hsCrP and NAMPT in this group (ESM Fig. [2](#MOESM5){ref-type=""}f). In multiple regression analyses, decrease in hsCrP (*β* = 0.65, *p* = 0.033) and decrease in BMI (*β* = 0.86, *p* = 0.029) were significant predictors for the NAMPT decrease, whereas decrease in WBC and basal WBC, hsCrP and BMI did not contribute (*R*^2^ = 0.83, *p* = 0.035 for the model).

Association of NAMPT with glucose metabolism {#Sec12}
--------------------------------------------

NAMPT significantly correlated with all variables of glucose and insulin metabolism (Table [1](#Tab1){ref-type="table"}, Fig. [2a, b](#Fig2){ref-type="fig"}). Children with impaired insulin sensitivity had higher NAMPT levels compared with normal insulin-sensitive children (Fig. [2c](#Fig2){ref-type="fig"}). When we adjusted for BMI SDS in partial correlation analyses, only mean blood glucose (BG) and AUC BG as dynamic variables during OGTT remained significant, but most other significances were lost (Table [1](#Tab1){ref-type="table"}). In multiple regression analyses, NAMPT was significantly associated with AUC BG (*β* = 0.24 ± 0.08, *p* = 0.004), whereas BMI SDS, age, sex and pubertal stage did not contribute significantly. Fig. 2NAMPT association with glucose/insulin metabolism. Correlation of NAMPT serum levels with AUC BG during OGTT (**a**) (*r* = 0.25, *p* = 0.001) and Matsuda ISI (**b**) (*r* = −0.29, *p* \< 0.001). White circles = lean children, black circles = obese children. **c** Children with impaired insulin sensitivity according to Matsuda ISI \< 4 (*n* = 44) had higher NAMPT levels compared with normal insulin sensitivity (*n* = 105, *p* = 0.003). Data are given as mean ± SEM and were analysed by *t* test of log-transformed NAMPT. **d** Correlation of NAMPT decline (given as mean ratio of NAMPT between 60--120 min to basal NAMPT) and Matsuda ISI (*r* = 0.48, *p* = 0.017). Course of blood glucose (**e**), insulin (**f**) and NAMPT (**g**) serum levels during OGTT in insulin-sensitive (*n* = 11) and insulin-resistant (*n* = 13) obese children. For NAMPT, data are given as ratio of NAMPT levels at single time points compared with basal NAMPT at *t* = 0 (*p*~Anova~ = 0.003). White circles, normal insulin; black circles, hyperinsulinemia. **h** Three-dimensional plot of NAMPT as a function of insulin-to-glucose ratio and time during OGTT

To investigate this finding in more detail, we analysed the dynamic of NAMPT serum concentrations during an OGTT in 24 obese adolescents (age 11.7 ± 4.1 years, BMI SDS 2.60 ± 0.53). Compared with basal levels, NAMPT levels declined to 77 ± 0.1% (*p* = 0.0029). This decline was stronger in the insulin-sensitive obese participants, as evidenced by a negative correlation of NAMPT with Matsuda ISI (Fig. [2d](#Fig2){ref-type="fig"}). We thus stratified groups into insulin-resistant and insulin-sensitive patients on the basis of peak insulin during OGTT \>1,000 and \<600 pmol/l, respectively (Fig. [2e, f](#Fig2){ref-type="fig"}). Accordingly, Matsuda ISI was significantly impaired in the hyperinsulinaemic group (8.02 ± 0.70 vs 2.59 ± 0.29, *p* \< 0.0001). There was no difference in the degree of obesity between the two groups (2.72 ± 0.11 vs 2.48 ± 0.20 BMI SDS, *p* \> 0.2). The decline of NAMPT, however, was significantly more pronounced in the insulin-sensitive group (Fig. [2g](#Fig2){ref-type="fig"}) and correlated with AUC-insulin-to-AUC-BG ratio (*r* = 0.43, *p* = 0.038). Likewise, individual NAMPT levels during OGTT correlated with the insulin-to-glucose ratio at each time point (*r* = −0.19, *p* = 0.034). Thus, NAMPT levels declined after an oral glucose load as a function of time and insulin-to-glucose ratio (Fig. [2h](#Fig2){ref-type="fig"}).

Association of NAMPT with cardiovascular parameters and leucocytes {#Sec13}
------------------------------------------------------------------

We assessed the correlation of NAMPT levels with cardiovascular variables (random and 24 h blood pressure), functional variables of early vascular impairment (IMT, endothelial function), and regenerative capacity (EPC count and migratory function) in our Atherobesity Childhood cohort. We identified significant correlations of NAMPT with systolic blood pressure and endothelial function that did, however, not withstand adjustment for BMI SDS in partial correlation analyses (Table [1](#Tab1){ref-type="table"}). By contrast, the cellular variables EPC and WBC counts, and hsCrP, were significantly associated with NAMPT serum levels (Fig. [3a, b](#Fig3){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). In multiple regression analyses, NAMPT was the strongest predictor for EPC as well as for WBC counts (Table [2](#Tab2){ref-type="table"}). Fig. 3NAMPT association with leucocytes in the Leipzig Atherobesity Childhood cohort. Correlation of NAMPT serum levels with EPC count (**a**) (*r* = −0.29, *p* \< 0.001) and hsCrP (**b**) (*r* = 0.34, *p* \< 0.001). Correlations of WBC count with metabolic variables AUC insulin (**c**) (*r* = 0.35, *p* \< 0.001) and Matsuda ISI (**d**) (*r* = −0.33, *p* \< 0.001). The strongest correlation was achieved between NAMPT and WBC count (**e**) (*r* = 0.46, *p* \< 0.001). White circles, lean children; black circles, obese children. Correlation coefficients were determined by Pearson correlation analyses of log-transformed variablesTable 2Multiple regression analyses for independent associations of NAMPT serum levelsStepVariable*R*^2^*β* ± SEM*B* ± SEM*p* valueDependent variable: log EPC count^a^1log NAMPT0.08−0.22 ± 0.10−0.23 ± 0.100.0232Leptin0.03−0.16 ± 0.10−0.007 ± 0.0040.0953Systolic BP SDS0.01−0.12 ± 0.09−0.07 ± 0.060.197Dependent variable: log WBC count^b^1log NAMPT0.2400.35 ± 0.080.15 ± 0.03\<0.0012log AUC~Ins~0.1050.40 ± 0.100.19 ± 0.05\<0.0013log EPC count0.022−0.16 ± 0.08−0.06 ± 0.030.0454Leptin0.015−0.21 ± 0.10−0.003 ± 0.0020.0465log hsCrP0.0140.13 ± 0.090.02 ± 0.010.124Dependent variable: log Matsuda ISI^c^1BMI SDS0.360−0.54 ± 0.06−0.23 ± 0.03\<0.0012log WBC0.070−0.26 ± 0.060.56 ± 0.14\<0.0013Age0.032−0.17 ± 0.06−0.03 ± 0.010.0064Sex0.0080.09 ± 0.060.11 ± 0.070.140StepVariable*R*^2^*β* ± SEM*B* ± SEM*p* valueDependent variable: log EPC count^a^1log NAMPT0.08−0.22 ± 0.10−0.23 ± 0.100.0232Leptin0.03−0.16 ± 0.10−0.007 ± 0.0040.0953Systolic BP SDS0.01−0.12 ± 0.09−0.07 ± 0.060.197Dependent variable: log WBC count^b^1log NAMPT0.2400.35 ± 0.080.15 ± 0.03\<0.0012log AUC~Ins~0.1050.40 ± 0.100.19 ± 0.05\<0.0013log EPC count0.022−0.16 ± 0.08−0.06 ± 0.030.0454Leptin0.015−0.21 ± 0.10−0.003 ± 0.0020.0465log hsCrP0.0140.13 ± 0.090.02 ± 0.010.124Dependent variable: log Matsuda ISI^c^1BMI SDS0.360−0.54 ± 0.06−0.23 ± 0.03\<0.0012log WBC0.070−0.26 ± 0.060.56 ± 0.14\<0.0013Age0.032−0.17 ± 0.06−0.03 ± 0.010.0064Sex0.0080.09 ± 0.060.11 ± 0.070.140Ins, insulin; PH, pubic hair stage^a^*R*^2^ = 0.12, *p* = 0.0019 (Childhood Atherobesity cohort, *n* = 156). Independent variables: BMI SDS, leptin, systolic BP SDS, log AUC~Ins~, log ISI, log hsCrP, log NAMPT, log EPC count^b^*R*^2^ = 0.40, *p* \< 0.0001(Childhood Atherobesity cohort, *n* = 156). Independent variables: BMI SDS, leptin, systolic BP SDS, log AUC~Ins~, log ISI, log hsCrP, log NAMPT, log EPC count^c^*R*^2^ = 0.47, *p* \< 0.0001(Childhood Atherobesity cohort, *n* = 156). Independent variables: BMI SDS, log NAMPT, log WBC, age, sex, PH

Considering this predominant association of NAMPT with WBCs, we hypothesised that WBCs may influence the associations of NAMPT with metabolic variables and evaluated the correlation of WBCs themselves with metabolic and cardiovascular variables. We identified significant BMI-independent correlations with AUC insulin, Matsuda ISI (Fig. [3c, d](#Fig3){ref-type="fig"}), systolic blood pressure (*r* = 0.18, *p* = 0.024), but most strongly with NAMPT serum levels (Fig. [3e](#Fig3){ref-type="fig"}). Likewise, in multiple regression analyses, WBCs contributed significantly and independently of age, sex and BMI SDS to Matsuda ISI (Table [2](#Tab2){ref-type="table"}).

Hence, NAMPT is most strongly associated with WBC count and WBCs themselves are significantly associated with variables of insulin resistance.

Expression pattern of NAMPT in tissues and leucocytes {#Sec14}
-----------------------------------------------------

Considering the strong association of circulating NAMPT levels with leucocytes in the clinical study, we systematically evaluated the expression pattern of *NAMPT* among 14 metabolically, endocrine and immunologically active tissues. We found that *NAMPT* mRNA was predominantly expressed in peripheral blood leucocytes (Fig. [4a](#Fig4){ref-type="fig"}). Fig. 4NAMPT expression pattern, production and secretion by leucocyte subpopulations. **a** The expression of *NAMPT* mRNA was significantly higher in PBL than in all other tissues, including adipose tissue and liver (*p*~Anova~ \< 0.0001). Significance was calculated by one-way ANOVA with Dunnett's post test (compared with PBL). **b** The mRNA expression of *NAMPT* was more than fivefold higher in granulocytes and monocytes compared with lymphocytes. **c** Higher amounts of NAMPT protein were detected in cell lysates of granulocytes and monocytes compared with lymphocytes. **d** Granulocytes secreted more than 22-fold higher amounts of NAMPT protein into cell culture supernatant fractions (*n* = 12) when normalised to total protein. Serum concentrations of NAMPT were highly correlated to leucocyte count in particular to neutrophil granulocyte (**e**) (*r* = 0.92, *p* = 0.009) and monocyte (**f**) (*r* = 0.94, *p* = 0.005) count but not to lymphocyte count (**g**) (*n* = 6, *p* = 0.41). **h** NAMPT enzymatic activity was present in cell lysates and supernatant fractions of all leucocyte subpopulations (*n* = 5). **i***SIRT1* mRNA expression was significantly higher in granulocytes compared with lymphocytes and monocytes (*n* = 12). **j** The release of NAMPT was significantly increased from monocytes and granulocytes after stimulation with 1 μg/ml LPS for 24 h in *n* = 3 independent experiments. Data are mean ± SEM. Statistical significance was assessed by Student's *t* test and Pearson correlation analysis: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.0001. G, granulocytes; L, lymphocytes; M, monocytes; PBL, peripheral blood leucocytes

To determine which subpopulation(s) of leucocytes potentially contribute to NAMPT levels in peripheral blood, we assessed *NAMPT* mRNA and NAMPT protein expression in granulocytes, lymphocytes and monocytes isolated from peripheral blood of 12 children and adolescents. The mRNA expression was more than fivefold higher in granulocytes and monocytes compared with lymphocytes (Fig. [4b](#Fig4){ref-type="fig"}). Consistent with this, we detected a higher amount of NAMPT protein in cell lysates of granulocytes and monocytes compared with lymphocytes (Fig. [4c](#Fig4){ref-type="fig"}). Granulocytes secreted highest amounts of NAMPT protein into cell culture supernatant fractions (Fig. [4d](#Fig4){ref-type="fig"}). Consistently, serum concentrations of NAMPT were highly correlated to leucocyte count, particularly to neutrophil granulocyte and monocyte count but not to lymphocyte count (Fig. [4e--g](#Fig4){ref-type="fig"}). Hence, NAMPT is predominantly produced and secreted by leucocytes, in particular by granulocytes.

NAMPT function and interaction with SIRT1 and LPS in distinct leucocyte subpopulations {#Sec15}
--------------------------------------------------------------------------------------

We evaluated the enzymatic activity of the NAMPT protein by quantification of nicotinamide mononucleotide (NMN) synthesis from nicotinamide and confirmed that NAMPT enzymatic activity was present in cell lysates and supernatant fractions of all leucocyte subpopulations (Fig. [4h](#Fig4){ref-type="fig"}).

To assess a downstream target of NAMPT activity, we examined *SIRT1* mRNA expression in the leucocyte subpopulations. The expression of *SIRT1* was significantly higher in granulocytes compared with lymphocytes and monocytes (Fig. [4i](#Fig4){ref-type="fig"}).

To finally evaluate whether NAMPT is stimulated by inflammatory agents, we analysed NAMPT release following stimulation with LPS. LPS significantly increased NAMPT release from monocytes and slightly enhanced NAMPT release from granulocytes (Fig. [4j](#Fig4){ref-type="fig"}).

Leucocyte counts and NAMPT release from leucocytes during OGTT {#Sec16}
--------------------------------------------------------------

We assessed whether the decline of NAMPT during OGTT is attributable to reduced leucocyte counts or reduced NAMPT release from leucocytes in 11 additional patients. The leucocyte, lymphocyte and neutrophil counts did not change significantly after oral glucose intake; only monocytes were significantly decreased after 60 min (ESM Fig. [3](#MOESM6){ref-type=""}a). Ex vivo, we found a slight decrease in NAMPT release after 120 min (ESM Fig. [3](#MOESM6){ref-type=""}b). Finally, to assess whether glucose has a direct effect on NAMPT release, we incubated isolated leucocytes with glucose, but we did not find significant changes (ESM Fig. [3](#MOESM6){ref-type=""}c).

Discussion {#Sec17}
==========

In this study, we showed that NAMPT is not only associated with obesity and glucose metabolism, but has the strongest relationship with leucocyte count and is in fact predominantly produced in leucocytes in its enzymatically active form. The circulating leucocyte count strongly correlated to insulin resistance, and the association of NAMPT with obesity and glucose metabolism may reflect an underlying relation with leucocytes.

Circulating NAMPT is affected by obesity and obesity intervention {#Sec18}
-----------------------------------------------------------------

NAMPT has drawn considerable interest in the fields of obesity, type 2 diabetes and inflammatory diseases. Some studies reported that circulating NAMPT is elevated in obesity and type 2 diabetes \[[@CR8], [@CR10]\], whereas others found no association with adiposity and metabolic variables \[[@CR9]\]. In our study, circulating NAMPT was significantly higher in obese compared with lean children, and correlated with the extent of obesity. If NAMPT is related to obesity, one would expect a decrease after weight loss, as has been shown by some studies \[[@CR8], [@CR29], [@CR30]\]. We show that NAMPT was reduced by significant weight loss after bariatric surgery but not by moderate weight loss due to lifestyle intervention. Exercise was also successful in reducing NAMPT levels as well as improving insulin sensitivity. Interestingly, bariatric surgery and exercise led to a concomitant reduction in WBC and hsCrP, and the decrease in NAMPT not only correlated with the decrease in BMI but also with the decrease in hsCrP. This suggests that in addition to a significant reduction in adipose tissue mass and/or insulin resistance, improvement in the inflammatory state may account for a reduction of NAMPT by interventions.

Circulating NAMPT declines after oral glucose provocation {#Sec19}
---------------------------------------------------------

NAMPT was associated with metabolic variables in our study. However, when analyses were adjusted for the degree of obesity, most associations were abolished, thus indicating that the correlation with insulin resistance was mainly secondary to obesity. Only dynamic variables of blood glucose during an OGTT remained significant after adjustment for BMI. Considering this finding, and that NAMPT has been shown to play a crucial role in beta cell function \[[@CR5]\], we investigated the acute response of NAMPT to oral glucose provocation. As NAMPT has been reported to be increased by hyperglycaemia through i.v. glucose infusions and experimentally in adipocytes \[[@CR31]\], one may expect an increase of NAMPT during an OGTT. Surprisingly, NAMPT levels declined following glucose challenge. Our results contrast with the findings of other studies, which reported a transient increase of NAMPT \[[@CR32]\] or have failed to demonstrate any NAMPT response during an OGTT \[[@CR33]\]. These contrasting findings may result from different patient characteristics, specifically the distinct degree of obesity, stratification for glucose vs for insulin resistance study, and in particular from the fact that all previous studies were performed in adults, whereas we investigated children. Children are at the beginning of the pathophysiologic development of insulin resistance and less biased by co-morbidities and their treatment; they may hence allow a better exploration of a potential association of NAMPT with glucose metabolism. Also different analytical methods need to be considered that have been shown to have a crucial impact on the quantification of NAMPT/visfatin \[[@CR27]\].

In our study, the decline of NAMPT was a function of time and insulin-to-glucose ratio. Time was the strongest predictor for the change of NAMPT serum concentration after glucose provocation. This may indicate that the natural circadian variation may affect NAMPT. A rhythmic oscillation in mRNA and protein levels of NAMPT was recently discovered \[[@CR34], [@CR35]\]. However, considering that: (1) NAMPT is lower with higher insulin-per-glucose secretion in our study; (2) our in vitro findings that did not show a stimulation of NAMPT release by glucose; and (3) the proposed role for NAMPT in beta cell function \[[@CR5]\], one may conclude that NAMPT augments glucose stimulated insulin secretion and is then negatively regulated by insulin. This feedback regulation seems to be disturbed in insulin-resistant participants, as the decline in NAMPT is predominant in insulin-resistant participants \[[@CR10], [@CR36]\]. In addition, other groups provided evidence that glucose directly downregulates NAMPT production in different cell types \[[@CR37], [@CR38]\]. Hence, the glucose stimulus and/or resulting insulin release and/or natural circadian variations in NAMPT levels may contribute to the decline of NAMPT in OGTT, although the precise mechanisms remain unclear at this point.

NAMPT is produced and secreted by leucocyte subpopulations {#Sec20}
----------------------------------------------------------

In our cross-sectional study, we found the strongest independent associations of circulating NAMPT with leucocyte counts. As there is no systematic evaluation of the origin of NAMPT so far, this prompted us to evaluate *NAMPT* expression among several metabolically, endocrine and immunologically active tissues. We found highest amounts of *NAMPT* mRNA in leucocytes compared with all other tissues, including adipose tissue and liver. Higher expression of *NAMPT* in non-fat cells and adipose tissue derived macrophages compared with fat cells has been reported before \[[@CR11], [@CR39]\], further supporting the hypothesis that adipose tissue is not the major source of NAMPT. We subsequently evaluated which leucocyte subpopulation(s) may account for the high NAMPT production and found that *NAMPT* mRNA expression was higher in granulocytes and monocytes compared with lymphocytes, and that granulocytes released significantly more NAMPT protein into cell culture supernatant fractions. Considering that neutrophil granulocytes constitute 50% to 60% of the total circulating WBCs, we hypothesise that granulocytes represent a major source of circulating NAMPT. To our knowledge, none of the previous clinical studies have adjusted their analyses for leucocyte counts, which may contribute to the conflicting results reported in the clinical studies so far.

NAMPT as a marker of low grade inflammation in obesity {#Sec21}
------------------------------------------------------

Given that leucocytes are a major source of circulating NAMPT, one may hypothesise that the increase of NAMPT in obese participants \[[@CR40], [@CR41]\] may be related to low-grade inflammation seen in obesity. This is substantiated by the association of NAMPT with inflammatory markers observed here, and in other studies \[[@CR42]\]. In addition, we demonstrated that LPS stimulated NAMPT production in monocytes and granulocytes, which is in line with a new study showing that NAMPT is induced in human macrophages \[[@CR43]\]. Taken together, this suggests a role for NAMPT and immune cells in chronic low grade inflammation observed in obesity and type 2 diabetes. These findings also indicate that the association of NAMPT with obesity and type 2 diabetes may be partly secondary to an underlying association of NAMPT with leucocytes.

This may in consequence have an impact on downstream targets, such as the NAD consuming factor SIRT1, which in turn has been shown to exert antiapoptotic effects \[[@CR3]\]. Supporting this hypothesis, *SIRT1* mRNA expression was significantly higher in granulocytes in our study, which may suggest that increased NAMPT levels delay apoptosis of granulocytes in obesity via induction of SIRT1. Another recent study has shown that NAMPT-mediated NAD biosynthesis plays a crucial role in myeloid differentiation in humans \[[@CR44]\]. These results may further explain the high correlation between circulating NAMPT and leucocyte counts, in that the high NAMPT levels may promote myeloid differentiation through SIRT1 and eventually increase the number of peripheral blood leucocyte counts. This would indicate that there is a mechanistic link between circulating NAMPT and leucocyte counts, and this may in consequence be relevant for the obesity-related increase in inflammatory status.

Leucocytes as major source of NAMPT: clinical implications {#Sec22}
----------------------------------------------------------

Our major new finding is that NAMPT is predominantly produced by leucocytes, independent from BMI. Interestingly, the decline of NAMPT after weight loss due to bariatric surgery, exercise \[[@CR45]\], and glucose provocation \[[@CR46]\] was paralleled by a decline in leucocyte counts. Furthermore we show that leucocytes per se, and independent from BMI, are associated with insulin sensitivity markers in obese children. Hence we speculate that this direct link between NAMPT and leucocytes may underlie the association between NAMPT and obesity and insulin resistance, and in particular the low-grade inflammatory state seen in these conditions. There is support for this notion from recent studies showing that NAMPT is related with systemic inflammation in diabetic patients \[[@CR47]\], that NAMPT serum concentrations and mRNA expression levels in leucocytes are increased in obese patients and that plasma NAMPT levels are related to inflammation in fatty liver disease \[[@CR48]\]. Finally, NAMPT was one of five markers that discriminated between patients with chronic inflammation and healthy controls \[[@CR49]\].

In summary, we not only provide clinical evidence on the association of NAMPT with obesity and obesity-related metabolic and cardiovascular sequelae in children, but show that NAMPT is acutely downregulated after glucose provocation. In particular, we identified leucocytes as a major source of enzymatically active NAMPT and reveal that the association of circulating NAMPT with leucocyte count outranges the one with obesity. This finding may be of particular importance linking obesity, inflammation and insulin resistance, for which NAMPT may be a marker or even a mediator.
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